ArticleVeterinary research2021
Microencapsulated phages show prolonged stability in gastrointestinal environments and high therapeutic efficiency to treat Escherichia coli O157:H7 infection.
Article in Veterinary research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Pooled it
- Bacteriophages and polymeric delivery systems: a mapping review.Folia microbiologica · 2026Review
- Prophage-encoding engineered bacteria enable prophylactic lytic phage therapy for enteric infection in mice.Nature microbiology · 2026Article
- Toxinotyping, Antibiotic Resistance Profile, and In Vitro Bio-Control ofAntibiotics (Basel, Switzerland) · 2026Article
- Assessing the impact of phage therapy on growth performance, microbiome and phage specific immune response in chickens.Scientific reports · 2026Article
- Preparation of sodium alginate-coated microencapsulated phage vB_SalP_SE29 and evaluation of its therapeutic effect onApplied and environmental microbiology · 2026Article
- Encapsulation of Bacteriophages in Alginate Beads: Improved Viability Under Harsh Simulated Gastric and Intestinal Conditions for Phage Therapy Applications.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Alginate encapsulation enhanced the gastrointestinal stability and bactericidal efficacy of an optimized Salmonella phage cocktail for oral delivery in poultry feed.Poultry science · 2026Article
- Recent insights on challenges encountered with phage therapy against gastrointestinal-associated infections.Gut pathogens · 2025Review
- Enhancing phage therapy by coating single bacteriophage-infected bacteria with polymer to preserve phage vitality.Nature biomedical engineering · 2025Article
- What, how, and why? - anti-EHEC phages and their application potential in medicine and food industry.Journal of applied genetics · 2025Review
- Oral feed-based administration of phage cocktail protects rohu fish (Labeo rohita) against Aeromonas hydrophila infection.Archives of microbiology · 2024Article
- Phage Delivery Strategies for Biocontrolling Human, Animal, and Plant Bacterial Infections: State of the Art.Pharmaceutics · 2024Review
- Genomic characterization, in vitro, and preclinical evaluation of two microencapsulated lytic phages VB_ST_E15 and VB_ST_SPNIS2 against clinical multidrug-resistant Salmonella serovars.Annals of clinical microbiology and antimicrobials · 2024Article
- Freeze-Drying of Encapsulated Bacteriophage T4 to Obtain Shelf-Stable Dry Preparations for Oral Application.Pharmaceutics · 2023Article
- Efficacy of Different Encapsulation Techniques on the Viability and Stability of Diverse Phage under Simulated Gastric Conditions.Microorganisms · 2023Article
- Holistic Strategies to ControlMicroorganisms · 2023Review
- Application of Physical-Chemical Approaches for Encapsulation of Active Substances in Pharmaceutical and Food Industries.Foods (Basel, Switzerland) · 2023Review
- Selection and characterization of bacteriophages specific toVeterinary world · 2022Article
- Isolation and Molecular Characterization of Two Novel Lytic Bacteriophages for the Biocontrol ofPharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Escherichia coli (E. coli) O157:H7 bacterial infection causes severe disease in mammals and results in substantial economic losses worldwide. Due to the development of antibiotic resistance, bacteriophage (phage) therapy has become an alternative to control O157:H7 infection. However, the therapeutic effects of phages are frequently disappointing because of their low resistance to the gastrointestinal environment. In this study, to improve the stability of phages in the gastrointestinal tract, E. coli O157:H7 phages were microencapsulated and their in vitro stability and in vivo therapeutic efficiency were investigated. The results showed that compared to free phages, the resistance of microencapsulated phages to simulated gastric fluid and bile salts significantly increased. The microencapsulated phages were efficiently released into simulated intestinal fluid, leading to a better therapeutic effect in rats infected with E. coli O157:H7 compared to the effects of the free phages. In addition, the microencapsulated phages were more stable during storage than the free phages, showing how phage microencapsulation can play an essential role in phage therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.